COCP

Business Context and Reporting Period

Company: Biozone Pharmaceuticals, Inc. (formerly International Surf Resorts, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2011

The Company underwent a significant strategic pivot in early 2011, changing its name and business focus from surf resorts to pharmaceuticals. Key transactions during the period included:

• March 1, 2011: Name change to Biozone Pharmaceuticals, Inc.
• May 16, 2011: Acquired assets and liabilities of Aero Pharmaceuticals, Inc. (dermatological products) for approximately $2 million in stock.
• June 30, 2011: Completed a "reverse acquisition" of the BioZone Lab Group (BioZone Labs, Equalan, Equachem, and BetaZone), a developer and manufacturer of OTC drugs and nutritional supplements. The BioZone Lab Group is the accounting acquirer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased by approximately 24% ($1.61 million) compared to the prior six-month period, attributed to delays in customer orders and decreased end-user demand.
• Margin Compression: Gross profit margin declined from 52% to 50% due to increased raw material costs.
• Operating Expenses: Increased by $340,343 (11%) primarily due to incremental payroll at BioZone Labs and transaction costs (legal, accounting, consulting) related to the acquisitions.
• Profitability: The Company swung from a net income of $138,762 in the prior year period to a net loss of $1.11 million, driven by lower gross profit and higher operating expenses.
• Liquidity Position: Cash balances increased significantly to $1.84 million, primarily due to $2.25 million in proceeds from convertible bridge notes and cash acquired in the Aero acquisition, offset by operating cash burn.

Outlook, Risks, and Contingencies

Going Concern Uncertainty

Management has raised substantial doubt about the Company's ability to continue as a going concern. Current cash balances are insufficient to meet working capital and capital expenditure needs for the next twelve months. The Company relies on external financing to fund operations and repay debt.

Debt Default and Liquidity Risks

• Bank Loan Default: As of August 15, 2011 (subsequent to period end), the Company is in default on four promissory notes totaling approximately $2.04 million. The default was triggered by the change in ownership of BioZone Labs and Equalan exceeding 25%. The lender has declared the entire amount immediately due and payable.
• Convertible Notes: The Company holds $2.25 million in 10% secured convertible bridge notes maturing on September 29, 2011. Failure to repay or convert these notes by maturity triggers a penalty fee.
• Personal Guarantees: The Company's President and Executive Vice President have personally guaranteed the repayment of the defaulted bank loans.

Internal Controls

Management concluded that disclosure controls and procedures were ineffective as of June 30, 2011, citing a lack of segregation of duties regarding cash disbursements due to limited accounting staff.

Investor Verification Checklist

• Debt Resolution: Verify the status of the $2.04 million bank loan default declared in August 2011 and whether a repayment plan or restructuring has been secured.
• Financing Status: Confirm if the $2.25 million convertible bridge notes maturing in late September 2011 have been repaid, converted, or extended.
• Going Concern Mitigation: Assess the progress of discussions with bankers and shareholders regarding new financing to cover the negative working capital of ~$1.1 million.
• Acquisition Integration: Review the operational integration of the BioZone Lab Group and Aero Pharmaceuticals to determine if revenue synergies are materializing to offset the increased operating costs.
• Equity Dilution: Monitor the issuance of additional shares, as the Company has issued significant stock for acquisitions and may need to issue more for financing, potentially diluting existing shareholders.